August 19, 2013
MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Clinical Cancer Experience with PET-MR
A terrific review of the clinical experience in cancer patents of the use of PET-MR was recently published by Drs. Karin Herrmann, Norbert Avril and Pablo Ros, among others. This detailed account summarizes many aspects of the clinical utility of PET-MR in more accurate detection of cancer and cancer metastasis, use in decision-making, comparisons of detection accuracy across cancers, and considerations of reduction in overall radiation imaging exposure, which may especially be an issue in patients with longer life expectancy and pediatric and young adult patients. Its use in minimal residual disease represents another area of ongoing interest.
I ask you to familiarize yourselves with this exciting imaging technology and to consider using this approach as an imaging component of your clinical trials. There are many remaining questions that need to be addressed.
For those at Seidman, the machine is now available for clinical use. Cleveland Clinic will be installing a similar PETMR soon.
Sequester Impact on Biomedical Research - Response from Sen. Brown
For the past couple weeks I have reminded you of the importance of contacting our political leaders to let them know the detrimental effect the sequester has had on research discoveries. One enthusiastic member of the Cancer Center community took the opportunity to write to Sen. Sherrod Brown and wanted to share the response they received back, with the hope that our governmental representatives will continue to push for support of the NIH:
NIH is the cornerstone of medical advancement and innovation in the United States, financing lifesaving research to improve the health and wellbeing of all Americans. I am highly supportive of the NIH's mission and am heartened by its successes. As such, I share your concern that NIH funding is taking a grave hit given budget cuts over the last few years and the effects of sequestration.
Not only are these cuts stifling innovation and research, but they are hurting job creation and may even have a lasting effect on the future workforce pipeline of medical researchers. The average age for a principal investigator (PI) receiving his or her first grant continues to increase, as does the average age for all PIs. In essence, we are losing scientists focusing on basic science and research on innovations that are not yet profitable enough to be championed by private industry. Maintaining robust funding levels for NIH is vitally important to reverse these trends.
I strongly support ample funding for NIH which is why I signed Senators Casey and Burr's FY14 appropriations letter. Funding NIH research will help advance groundbreaking discoveries that lead to better understanding of disease processes, treatments, and health outcomes for Americans. As this year's appropriations process moves forward, please be assured that I will continue to advocate for ample funding for NIH.
Thank you again for getting in touch with me.
CASE CCC IN THE NEWS
Tax-PF Superior to PF as Induction Therapy in HNSCC
Long-term Study of Drug Finasteride Shows Safety, Effectiveness in Lowering Prostate Cancer Risk
Breast Cancer Battle: New Tool is Saving Lives
Kidney Function May Not Affect Vidaza's Safety And Efficacy In Higher-Risk MDS Patients
AXIS Trial: Second-Line Axitinib Versus Sorafenib
Less Aggressive Prostate Cancer Tumors Tend to Stay that Way Over Time, Study Shows
Lack of Elderly Patients in Cancer Trials Leads to Inadequate Treatment Guidance
MARK YOUR CALENDARS
Graft-versus-Host Disease (GvHD) National Symposium
Registration is open for the Graft-versus-Host Disease (GvHD) National Symposium, Friday, November 1 at the Embassy Suites Cleveland. This conference is intended to raise awareness about the signs and symptoms of GvHD, review cutting edge approaches to prevention and treatment, and highlight and promote research to further our understanding of its cause. The symposium will have two tracks: a scientifically rigorous one for physicians and practitioners, and a survivor track that will focus on challenges faced by BMT recipients and their families. CME credit is available.
This symposium will also feature a poster session. Abstracts should be submitted no later than Friday, September 27 at 5:00 pm to firstname.lastname@example.org. Abstracts will be published in a booklet or the syllabus, which will be given to all participants. Prizes will be awarded. The registration fee for invited presenters is complimentary, but advance registration is required.
Case Comprehensive Cancer Center Microscope Usage Survey
We are attempting to determine microscope usage among Cancer Center members to more fully meet your research needs. We are especially interested in determining your needs for super resolution microscopy. Advances in microscopy and cell biology are intimately intertwined, with new visualization possibilities leading to dramatic leaps in our understanding of how cells function. The recent advances in super resolution microscopy have changed the limits of optical resolution from 250 nm to 20 nm. Biologists are no longer limited to inferring molecular interactions, as it is now possible to see the individual molecules as they interact. We would like to know your interest in bringing super resolution technology to our campus. Please take a few minutes to complete a survey on microscopes and specifically to your need for super resolution microscopy.
Publication Support Acknowledgement
Please remember to acknowledge the valuable support provided by the Cancer Center and its core facilities in your research papers and publications:
"This research was supported by the Case Comprehensive Cancer Center (P30CA043703)." OR
"This research was supported by the [insert facility name] Core Facility of the Case Comprehensive Cancer Center (P30CA043703)."
Melanoma Research Alliance
The Melanoma Research Alliance (MRA) announces its seventh annual Request for Proposals (RFP), soliciting translational research grant applications from scientists and clinicians around the world. The RFP calls for ideas that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment.
Fourth Annual DeGregorio Foundation Award for Cancers of the Upper GI Tract
The DeGregorio Family Foundation for Gastric and Esophageal Cancer is pleased to announce the 4th annual funding opportunity for gastroesophageal malignancies. The Foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis, and treatment of upper gastrointestinal malignancies. We support high quality, innovative, and transformative translational and bent research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment.
Special Pathology Lecture
Pathology Research Seminar Series
Cancer Biology Staff/Candidate Seminar
Department of Neurosciences - Mid Term Evaluation Seminar
Hematology and Oncology Division Research Conference
Molecular Genetics Seminar
Stem Cell Biology and Regenerative Medicine
Cancer Center Research in Progress will resume in September
Taussig Cancer Institute Grand Rounds will resume in September
Hematology/Oncology Fellows Conference/Curriculum Series
Pathology Dissertation Defense
Cancer Center Seminar Series
Radiation Oncology Physics Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
ADDITIONAL UPCOMING SEMINARS & EVENTS
MSC 2013: Adult Stem Cell Therapy & Regenerative Medicine
Molecular Genetics Guest Speaker
New Directions in Melanoma and Non-Melanoma Skin Cancers
National GvHD Health Symposium
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Prevent Cancer Foundation Grants and Fellowships
Leukemia & Lymphoma Society Special Fellow
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.